Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MONSTAR-SCREEN-3 preliminary RCC cohort detects baseline ctDNA with a whole-genome assay

A preliminary ASCO GU 2026 report from MONSTAR-SCREEN-3, with results available for 16 of 30 enrolled patients with resectable renal cell carcinoma, found baseline ctDNA in 16 of 16 evaluable patients using a tumor-informed whole-genome assay, including 9 of 16 below 100 parts per million.

Journal of Clinical Oncology